Abstract
Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and resistance to daunorubicin in B-ALL cells through activation of Akt signaling. Th17 cells may represent a novel target to improve B-ALL immunotherapy.
Introduction
B-cell acute lymphoblastic leukemia (B-ALL) is a malignancy of the blood and bone marrow characterized by the overproduction of immature white blood cells. While pediatric patients often achieve high cure rates, the prognosis for adults remains poor due to frequent relapses and drug resistance. Recent research has pivoted toward the "tumor microenvironment"—the complex ecosystem of cells and chemicals surrounding the cancer—to understand treatment failure. This study investigates the role of Th17 cells, a subset of helper T cells typically involved in inflammation and fungal defense, in the progression of B-ALL.
Methods
The researchers employed a multi-faceted approach using clinical samples and laboratory models:
- Clinical Analysis: Peripheral blood (PB) and bone marrow (BM) were analyzed from 44 newly diagnosed B-ALL patients and 25 healthy donors (HD).
- Flow Cytometry: Used to quantify T-cell subsets (Th17 vs. Th1) based on surface markers and intracellular cytokine production.
- Molecular Assays: ELISA and RT-PCR measured cytokine levels and gene expression, while Western blotting identified the activation of survival pathways like Akt and Stat3.
- Functional Studies: The Nalm-6 B-ALL cell line and primary patient cells were used to test the impact of IL-17A on cell growth and apoptosis during daunorubicin treatment.
Results
The Th17/Th1 Imbalance and Clinical Correlation
In healthy individuals, a balance exists between Th1 cells (anti-tumor) and Th17 cells. In B-ALL patients, this balance is significantly skewed. Th17 cells were found to be significantly increased in both PB and BM of B-ALL patients compared to healthy controls, while Th1 cells were reduced. Notably, when patients achieved complete remission (CR), their Th17 cell levels dropped significantly, suggesting a direct link between these cells and disease activity.
Cytokine Surge and Chemoresistance
The study observed a significant surge in IL-17A levels in the blood and bone marrow of B-ALL patients. This cytokine appears to act as a protective shield for leukemia cells. Treatment with IL-17A significantly reduced the rate of apoptosis (programmed cell death) induced by the chemotherapy drug daunorubicin. In Nalm-6 cells, the addition of IL-17A increased cell viability from approximately 65% to 80% following daunorubicin exposure.
Mechanism: Akt Signaling
The primary mechanism for this resistance is the activation of the Akt signaling pathway. IL-17A keeps this survival pathway "on," preventing chemotherapy from effectively killing the cancer cells. The researchers demonstrated that using Akt inhibitors (such as LY294002) could reverse this effect, restoring the sensitivity of leukemia cells to daunorubicin.
Conclusion
This study identifies Th17 cells and their primary cytokine, IL-17A, as critical components of the B-ALL tumor microenvironment that promote cancer cell survival and drug resistance. While further in vivo studies and larger clinical cohorts are necessary, these findings suggest that targeting the Th17/IL-17A axis—potentially through existing FDA-approved drugs—could provide a novel strategy to overcome chemoresistance in B-ALL patients.
Summary updated